Baveno VI和VII标准不适用于肝细胞癌患者的大静脉曲张或临床显著门静脉高压筛查
该回顾性研究纳入185例Child-Pugh A级肝硬化合并肝细胞癌患者,评估Baveno VI和VII标准的诊断性能。结果显示,符合Baveno VI有利标准的患者中8%存在大食管静脉曲张,符合Baveno VII有利标准的患者中23%存在临床显著门静脉高压。结论认为这些标准不适用于肝细胞癌患者。
要点
- Baveno VI有利标准(LSM<20 kPa且血小板>150 G/L)不能排除大食管静脉曲张。
- Baveno VII有利标准(LSM≤15 kPa且血小板≥150 G/L)不能排除临床显著门静脉高压。
- LSM≥25 kPa用于确认临床显著门静脉高压的特异性仅为48%。
核心结论
- Baveno VI有利标准不适合排除高风险食管静脉曲张,Baveno VII标准不适合排除或确认肝细胞癌患者的临床显著门静脉高压。
研究设计与样本
- 回顾性纳入185例Child-Pugh A级肝硬化合并肝细胞癌患者,且在6个月内接受内镜、肝脏硬度测量和血小板计数检查。
- 患者按BCLC分期分类:46%为BCLC-0/A,28%为BCLC-B,26%为BCLC-C。
主要发现
- 食管静脉曲张存在于44%的患者中(23%为大静脉曲张),HVPG≥10 mm Hg存在于42%的患者中(平均8 mm Hg)。
- 符合Baveno VI有利标准的患者中,全队列8%存在大食管静脉曲张(敏感性93%,阴性预测值92%),BCLC-0-A亚组11%(敏感性89%,阴性预测值89%),BCLC-C亚组10.0%(敏感性91%,阴性预测值90%)。
- HVPG<10 mm Hg的患者中,6%存在大食管静脉曲张,17%存在小食管静脉曲张。
- 符合Baveno VII有利标准的患者中,全队列23%存在临床显著门静脉高压,BCLC-0/A亚组为25%。
- LSM≥25 kPa用于确认临床显著门静脉高压的特异性为48%。
关键数值与推荐
- Baveno VI有利标准定义为LSM<20 kPa且血小板>150 G/L,用于排除大食管静脉曲张。
- Baveno VII有利标准定义为LSM≤15 kPa且血小板≥150 G/L,用于排除临床显著门静脉高压。
- 临床显著门静脉高压定义为HVPG≥10 mm Hg。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Baveno VI and VII criteria are used in patients with cirrhosis to rule out large size oesophageal varices (EV) and rule in/out clinically significant portal hypertension (CSPH). AIM: To evaluate their diagnostic performance in these patients. METHODS: We retrospectively included all patients with Child-Pugh A cirrhosis and HCC who had endoscopy, liver stiffness measurement (LSM) and platelet count within 6 months. They were classified according to the BCLC stage. Favourable Baveno VI criteria were defined by LSM < 20 kPa and platelets > 150 G/L (to rule out large EV), favourable Baveno VII criteria if LSM ≤ 15 kPa and platelets ≥ 150 G/L (to rule out CSPH, which was defined by a HVPG ≥ 10 mm Hg. RESULTS: We included 185 patients; 46% were BCLC-0/A, 28% BCLC-B and 26% BCLC-C. EV were present in 44% (23% large), and HVPG ≥ 10 mm Hg in 42% (mean 8 mm Hg). In patients with favourable Baveno VI criteria, 8% of the whole cohort (Se 93%, NPV 92%), 11% of BCLC-0-A (Se 89%, NPV 89%) and 10.0% of BCLC-C patients (Se 91%, NPV 90%) had large EV. Among patients with HVPG < 10 mm Hg, 6% had large EV and 17% small. CSPH was present in 23% of patients with favourable Baveno VII criteria among the whole cohort, and in 25% of those with BCLC-0/A. The specificity of LSM ≥ 25 kPa to rule in CSPH was 48%. CONCLUSIONS: Favourable Baveno VI criteria are not appropriate to rule out the presence of high-risk EV, or Baveno VII criteria to rule CSPH in/out in patients with HCC.
引用
- Allaire M, Campion B, Demory A, et al. Baveno VI and VII criteria are not suitable for screening for large varices or clinically significant portal hypertension in patients with hepatocellular carcinoma. Aliment Pharmacol Ther. 2023. PMID: 37300315. doi:10.1111/apt.17599
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。